The Next Generation of Cannabinoid Production.
David Kideckel, PhD, MBA 647-776-8240
We are initiating coverage on Willow Biosciences Inc. (“Willow,” “WLLW,” “Company”) with a Speculative Buy rating and a $5.00/sh price target.
Initiating Coverage with a $5.00 Price Target and a Speculative Buy Rating
We are initiating coverage on WLLW with a Speculative Buy rating, and a 12-month price target of $5.00/sh, based on our discounted cash flow valuation, using a 20% discount rate and 3.0% terminal growth rate. Our rating is reflective of the process and regulatory risk associated with the use of biosynthesis for producing cannabinoids and demand uncertainty for biosynthetically produced cannabinoids.
© 2020 ATB Capital Markets Inc. All Rights Reserved. ATB Capital Markets Inc. is a member of IIROC and CIPF (Canada) and ATB Capital Markets USA Inc. is a member of FINRA and SIPC (USA).
ATB Business is a unit of ATB Financial which provides financial services to commercial enterprises from small businesses to corporates.